Exploring Statins to Decrease HIV-Related Heart Disease Risk.

M. Mitka

DOI: https://doi.org/10.1001/jama.2015.5498

2015-08-18

Abstract:Antiretroviral therapy (ART) has been a lifeline for untold numbers o f p a t i e n t s w i t h H I V. B u t a s mounting evidence shows the infection may increase their risk of cardiovascular disease with age, new research is targeting statins as a potential preventive agent for people living with HIV. Even when investigators have controlled for traditional risk factors such as elevated cholesterol, hypertension, and smoking, their findings suggest patients with HIV are significantly more likely to have myocardial infarctions or other types of cardiovascular disease than those without the infection. For example, data from 82 459 participants in the Veterans Aging Cohort Study showed that after nearly 6 years of follow-up, participants with HIV and no baseline cardiovascular disease had a 50% increased risk of acute myocardial infarction compared with participants who didn’t have HIV or heart disease (Freiberg MS et al. JAMA Intern Med. 2013; 173[8]:614-622). Researchers estimate 20% of patients with HIV currently take statins to lower their low-density lipoprotein cholesterol (LDL-C) levels, but no evidence is currently available that suggests statins may lower HIV-related cardiovascular disease risk. However, 2 small studies, 1 published and the other presented earlier this year at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI), suggest statin therapy may help reduce heart disease risk in this patient population. In the f irst study, a randomized, double-blind, placebo-controlled trial, 40 participants with HIV and subclinical coronary atherosclerosis (LDL-C <130 mg/d with evidence of arterial inflammation in the aorta by fluorodeoxyglucose positron emission tomography) were given either placebo or atorvastatin (20 mg/d in the first 3 months, increasing to 40 mg/d for months 4-12) for 1 year. The researchers found statin therapy reduced noncalcified plaque volume and high-risk coronary plaque features compared with placebo. They noted that although their findings are promising, the number of study participants was small and further studies are needed to assess whether reducing noncalcified plaque volume and high-risk coronary plaque features can prevent cardiovascular events in patients with HIV (Lo J et al. Lancet HIV. 2015;2[2]: e52e63). The second study, also double-blinded, enrolled 147 patients with HIV infection who were taking stable ART and had LDL-C levels of 130 mg/dL or less and heightened T-cell activation or increased inflammation measured by high-sensitivity C-reactive protein levels ( 2 mg/L). Participants were randomized to receive either placebo or 10 mg daily of rosuvastatin. Researchers found that statin therapy halted progression of carotid artery (intima and media) thickening, a measure of the extent of atherosclerotic vascular disease, in patients with HIV. The investigators noted that their findings justify further clinical trials of statin u s e fo r p a t i e n t s w i t h H I V i n fe c t i o n (Longenecker C et al. Oral Abstract presented at: CROI 2015. http://bit . ly /1PomN4E). Cardiovascular Disease Prevention With such promising findings, researchers have launched the largest clinical trial to date investigating whether statin therapy can prevent HIV-related cardiovascular disease (http://reprievetrial.org/overview/). The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is enrolling 6500 women and men aged 40 to 75 years (22% female, 43% black individuals) who are infected with HIV-1 and are asymptomatic for cardiovascular disease. About 100 sites in the United States, Canada, Puerto Rico, and Thailand will participate, with about 80% to 90% of study enrollees coming from the US sites. The $40 million REPRIEVE trial is funded primarily by the National Institutes of Health’s National Heart, Lung, and Blood Institute (NHLBI) in collaboration with the AIDS Clinical Trials Group and support from the National Institute of Allergy and Infectious Diseases (NIAID). Kowa Pharmaceuticals America, manufacturer of pitavastatin, is donating the study drug and placebo and also offering some funding. The study comes amidst efforts News & Analysis